Engineered immune cells take aim at hard-to-treat cancers

NCT ID NCT07297160

First seen Jan 04, 2026 · Last updated Jun 15, 2026 · Updated 26 times

Summary

This early-phase study tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have returned or not responded to standard treatments. The treatment involves taking a patient's own immune cells (T cells), modifying them in the lab to recognize and attack cancer cells that carry the CD70 protein, and then giving them back to the patient. The main goals are to find a safe dose and understand side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

  • The Methodist Hospital

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.